Cargando…

Lifetime use of nonsteroidal anti-inflammatory drugs and breast cancer risk: results from a prospective study of women with a sister with breast cancer

BACKGROUND: Nonsteroidal anti-inflammatory drugs (NSAIDs) have been shown to inhibit several pathways in experimental models of breast carcinogenesis, but epidemiological evidence remains insufficient to support their use for breast cancer prevention. We examined the association between use of NSAID...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Sangmi, Shore, David L., Wilson, Lauren E., Sanniez, Ethel I., Kim, Jae H., Taylor, Jack A., Sandler, Dale P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4682256/
https://www.ncbi.nlm.nih.gov/pubmed/26673874
http://dx.doi.org/10.1186/s12885-015-1979-1
_version_ 1782405867370446848
author Kim, Sangmi
Shore, David L.
Wilson, Lauren E.
Sanniez, Ethel I.
Kim, Jae H.
Taylor, Jack A.
Sandler, Dale P.
author_facet Kim, Sangmi
Shore, David L.
Wilson, Lauren E.
Sanniez, Ethel I.
Kim, Jae H.
Taylor, Jack A.
Sandler, Dale P.
author_sort Kim, Sangmi
collection PubMed
description BACKGROUND: Nonsteroidal anti-inflammatory drugs (NSAIDs) have been shown to inhibit several pathways in experimental models of breast carcinogenesis, but epidemiological evidence remains insufficient to support their use for breast cancer prevention. We examined the association between use of NSAIDs and breast cancer risk in a prospective cohort. METHODS: The Sister Study is a prospective cohort study of women who had a sister(s) with breast cancer. As of December 2013, 2118 incident breast cancers were ascertained from 50,884 women enrolled between 2003 and 2009. Lifetime history of NSAID use was estimated from self-reported data in pill-years, with 1 pill per week for a year equivalent to 1 pill-year. Cox regression models were used to estimate hazard ratios (HRs) of breast cancer in relation to pill-years of use for different NSAIDs, with adjustment for potential confounders. RESULTS: In the full cohort, although there was some evidence that use of non-aspirin, non-COXib NSAIDs was associated with lower breast cancer risk, there was little evidence of overall association for most categories of NSAID use. Among postmenopausal women NSAID use was not associated with reduced risk of breast cancer. However, among premenopausal women there was significantly reduced risk for any NSAID (HR(4vs1) = 0.66, 95 % CI: 0.50–0.87) and specifically for aspirin (HR(4vs1) = 0.57, 95 % CI: 0.33–0.98), with small, but non-significant reductions in risk for other drug classes. CONCLUSION: Women with a sister with breast cancer are themselves at increased risk and might benefit the most from chemoprevention. Although there was little evidence of protective effect from NSAIDs in the overall cohort of women or among the subset who are postmenopausal, there is intriguing evidence that NSAID use, particularly aspirin, may reduce risk among premenopausal women. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-015-1979-1) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4682256
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-46822562015-12-18 Lifetime use of nonsteroidal anti-inflammatory drugs and breast cancer risk: results from a prospective study of women with a sister with breast cancer Kim, Sangmi Shore, David L. Wilson, Lauren E. Sanniez, Ethel I. Kim, Jae H. Taylor, Jack A. Sandler, Dale P. BMC Cancer Research Article BACKGROUND: Nonsteroidal anti-inflammatory drugs (NSAIDs) have been shown to inhibit several pathways in experimental models of breast carcinogenesis, but epidemiological evidence remains insufficient to support their use for breast cancer prevention. We examined the association between use of NSAIDs and breast cancer risk in a prospective cohort. METHODS: The Sister Study is a prospective cohort study of women who had a sister(s) with breast cancer. As of December 2013, 2118 incident breast cancers were ascertained from 50,884 women enrolled between 2003 and 2009. Lifetime history of NSAID use was estimated from self-reported data in pill-years, with 1 pill per week for a year equivalent to 1 pill-year. Cox regression models were used to estimate hazard ratios (HRs) of breast cancer in relation to pill-years of use for different NSAIDs, with adjustment for potential confounders. RESULTS: In the full cohort, although there was some evidence that use of non-aspirin, non-COXib NSAIDs was associated with lower breast cancer risk, there was little evidence of overall association for most categories of NSAID use. Among postmenopausal women NSAID use was not associated with reduced risk of breast cancer. However, among premenopausal women there was significantly reduced risk for any NSAID (HR(4vs1) = 0.66, 95 % CI: 0.50–0.87) and specifically for aspirin (HR(4vs1) = 0.57, 95 % CI: 0.33–0.98), with small, but non-significant reductions in risk for other drug classes. CONCLUSION: Women with a sister with breast cancer are themselves at increased risk and might benefit the most from chemoprevention. Although there was little evidence of protective effect from NSAIDs in the overall cohort of women or among the subset who are postmenopausal, there is intriguing evidence that NSAID use, particularly aspirin, may reduce risk among premenopausal women. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-015-1979-1) contains supplementary material, which is available to authorized users. BioMed Central 2015-12-16 /pmc/articles/PMC4682256/ /pubmed/26673874 http://dx.doi.org/10.1186/s12885-015-1979-1 Text en © Kim et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Kim, Sangmi
Shore, David L.
Wilson, Lauren E.
Sanniez, Ethel I.
Kim, Jae H.
Taylor, Jack A.
Sandler, Dale P.
Lifetime use of nonsteroidal anti-inflammatory drugs and breast cancer risk: results from a prospective study of women with a sister with breast cancer
title Lifetime use of nonsteroidal anti-inflammatory drugs and breast cancer risk: results from a prospective study of women with a sister with breast cancer
title_full Lifetime use of nonsteroidal anti-inflammatory drugs and breast cancer risk: results from a prospective study of women with a sister with breast cancer
title_fullStr Lifetime use of nonsteroidal anti-inflammatory drugs and breast cancer risk: results from a prospective study of women with a sister with breast cancer
title_full_unstemmed Lifetime use of nonsteroidal anti-inflammatory drugs and breast cancer risk: results from a prospective study of women with a sister with breast cancer
title_short Lifetime use of nonsteroidal anti-inflammatory drugs and breast cancer risk: results from a prospective study of women with a sister with breast cancer
title_sort lifetime use of nonsteroidal anti-inflammatory drugs and breast cancer risk: results from a prospective study of women with a sister with breast cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4682256/
https://www.ncbi.nlm.nih.gov/pubmed/26673874
http://dx.doi.org/10.1186/s12885-015-1979-1
work_keys_str_mv AT kimsangmi lifetimeuseofnonsteroidalantiinflammatorydrugsandbreastcancerriskresultsfromaprospectivestudyofwomenwithasisterwithbreastcancer
AT shoredavidl lifetimeuseofnonsteroidalantiinflammatorydrugsandbreastcancerriskresultsfromaprospectivestudyofwomenwithasisterwithbreastcancer
AT wilsonlaurene lifetimeuseofnonsteroidalantiinflammatorydrugsandbreastcancerriskresultsfromaprospectivestudyofwomenwithasisterwithbreastcancer
AT sanniezetheli lifetimeuseofnonsteroidalantiinflammatorydrugsandbreastcancerriskresultsfromaprospectivestudyofwomenwithasisterwithbreastcancer
AT kimjaeh lifetimeuseofnonsteroidalantiinflammatorydrugsandbreastcancerriskresultsfromaprospectivestudyofwomenwithasisterwithbreastcancer
AT taylorjacka lifetimeuseofnonsteroidalantiinflammatorydrugsandbreastcancerriskresultsfromaprospectivestudyofwomenwithasisterwithbreastcancer
AT sandlerdalep lifetimeuseofnonsteroidalantiinflammatorydrugsandbreastcancerriskresultsfromaprospectivestudyofwomenwithasisterwithbreastcancer